Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Cancer Research UK Phase I Trial of IMA950 (A Novel Multi-Peptide Vaccine) Plus GM-CSF in Patients With Newly Diagnosed Glioblastoma

Next Previous
Trial Profile

A Cancer Research UK Phase I Trial of IMA950 (A Novel Multi-Peptide Vaccine) Plus GM-CSF in Patients With Newly Diagnosed Glioblastoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMA 950 (Primary) ; Sargramostim; Temozolomide
  • Indications Astrocytoma; Glioblastoma
  • Focus Adverse reactions; First in man; Pharmacodynamics

Most Recent Events

  • 25 May 2016 Primary endpoint has been met. (Total number of patients showing patient-individual T-cell responses against a single or multiple tumor-associated peptides (TUMAP) contained in the study vaccine IMA950 at one or more post-vaccination time points by HLA multimer analysis), as per results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
  • 25 May 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
  • 04 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top